ZFHN Portfolio Company PPS enters the US Market

2019-04-17T11:59:43+02:00April 17th, 2019|

Protagen Protein Services joins forces with American specialist

Heilbronn/Boston, April 17, 2019 – Protagen Protein Services GmbH (PPS), a leading provider of contract analysis services in the field of protein research, has entered the important North American market. The merger with BioAnalytix Inc. from Cambridge near Boston will create a leading global provider of analytical services for the biopharmaceutical industry. Since 2005, Zukunftsfonds Heilbronn (ZFHN) has been a majority shareholder of PPS.

PPS and BioAnalytix have a lot of experience

PPS has a comprehensive range of validated analytical methods at its disposal for renowned companies in the pharmaceutical, biotechnology and life sciences industries. The Heilbronn-and Dortmund based company also supports the development of so-called biosimilars through its analytics and offers a range of services relating to biologics and the evaluation of biotherapeutics. BioAnalytix is a specialist analytical services company that collaborates with leading biotherapy companies in the development and application of advanced analytical techniques and data analysis of complex biologics.

Both companies complement each other ideally

“Both companies complement each other ideally. We are now able to offer a full portfolio of analytical services for the development of highly effective protein-based drugs in US and EU terrritory., Our company gains access to the important North American market, which has been growing strongly for years. It was very important for us to select Boston as the hub of biotech and pharma worldwide.,” explains Martin Blüggel, Managing Director of PPS.

“Our participation in PPS has been a great pleasure for us for many years. The company has earned itself an excellent reputation. The step to North America was logical and consistent,” explains Thomas R. Villinger, CEO of ZFHN.